



KINETA

Innovation From Within™

PRESS RELEASE

Kineta Wins Three NIH Therapeutic Discovery Grants

More than \$730 thousand directed at autoimmune and antiviral programs.

SEATTLE, WA, November 4, 2010 – Kineta announced today it has been awarded three Qualifying Therapeutic Discovery Program (QTDP) grants from the Internal Revenue Service (IRS) providing additional non-dilutive government support for two of Kineta's antiviral programs and its lead autoimmune program.

"These grants bring an infusion of government funding and powerful validation to Kineta's high caliber drug development programs. We are particularly thankful to the Washington State delegation that supported and advanced this valuable program for the biotech industry," said Kineta President and Chief Executive Officer, Charles L. Magness, Ph.D. The funding will be directed at ShK-186 targeting multiple sclerosis and type 1 diabetes mellitus, ROAS1 targeting influenza and Kineta's discovery stage RIG-I program developing a broad based antiviral drug targeting multiple viruses.

The QTDP is an element of the Patient Protection and Affordable Care Act passed by the US Congress earlier this year. The grants are designed to support projects that show promise to result in new therapies to treat unmet medical needs and have potential to create high quality jobs and advance U.S. competitiveness.

For more information on today's announcement, contact Meg O'Connor, Director of Corporate Communications, moconor@kinetabio.com, 206-251- 8638.

#####

Kineta, Inc. is a Seattle-based privately held biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system. Our world class scientists are pioneers in developing life-changing classes of drugs that harness the power of the immune system to fight disease. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases. Our progressive business model focuses on targeting unmet medical needs and rapid achievement of important clinical milestones. For more information on Kineta, Inc. visit our website, www.Kinetabio.com